公开(公告)号：US11046688B2

公开(公告)日：2021-06-29

申请号：US16598717

申请日：2019-10-10

Applicant: Cancer Research Technology Limited

Inventor： Swen Hoelder ,  Julian Blagg ,  Savade Solanki ,  Hannah Woodward ,  Sebastien Gaston Andre Naud ,  Vassilios Bavetsias ,  Peter Sheldrake ,  Paolo Innocenti ,  Kwai-Ming J. Cheung ,  Butrus Atrash

IPC: A61K31/519 ,  C07D471/04 ,  C07D401/14 ,  C07D413/14 ,  C07D401/04 ,  C07D405/04 ,  C07D519/00

Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

公开(公告)号：US20200165241A1

公开(公告)日：2020-05-28

申请号：US16598717

申请日：2019-10-10

Applicant: Cancer Research Technology Limited

Inventor： Swen Hoelder ,  Julian Blagg ,  Savade Solanki ,  Hannah Woodward ,  Sebastien Gaston Andre Naud ,  Vassilios Bavetsias ,  Peter Sheldrake ,  Paolo Innocenti ,  Kwai-Ming J. Cheung ,  Butrus Atrash

IPC: C07D471/04 ,  A61K31/519 ,  C07D519/00 ,  C07D405/04 ,  C07D401/04 ,  C07D413/14 ,  C07D401/14

Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

公开(公告)号：US20220402912A1

公开(公告)日：2022-12-22

申请号：US17319231

申请日：2021-05-13

Applicant: Cancer Research Technology Limited

Inventor： Swen Hoelder ,  Julian Blagg ,  Savade Solanki ,  Hannah Woodward ,  Sebastien Gaston Andre Naud ,  Vassilios Bavetsias ,  Peter Sheldrake ,  Paolo Innocenti ,  Kwai-Ming J. Cheung ,  Butrus Atrash

IPC: C07D471/04 ,  A61K31/519 ,  C07D413/14 ,  C07D401/14 ,  C07D405/04 ,  C07D401/04 ,  C07D519/00

Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

公开(公告)号：US11897877B2

公开(公告)日：2024-02-13

申请号：US17319231

申请日：2021-05-13

Applicant: Cancer Research Technology Limited

Inventor： Swen Hoelder ,  Julian Blagg ,  Savade Solanki ,  Hannah Woodward ,  Sebastien Gaston Andre Naud ,  Vassilios Bavetsias ,  Peter Sheldrake ,  Paolo Innocenti ,  Kwai-Ming J. Cheung ,  Butrus Atrash

IPC: C07D471/04 ,  C07D401/14 ,  C07D413/14 ,  C07D401/04 ,  C07D405/04 ,  C07D519/00 ,  A61K31/519

CPC classification number: C07D471/04 ,  A61K31/519 ,  C07D401/04 ,  C07D401/14 ,  C07D405/04 ,  C07D413/14 ,  C07D519/00

Abstract: The present invention relates to compounds of formula I




wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.